Neumora Therapeutics, Inc. (NMRA)
NASDAQ: NMRA · Real-Time Price · USD
0.3470
-0.0198 (-5.40%)
At close: Nov 19, 2026, 4:00 PM EST
0.3600
+0.0130 (3.75%)
After-hours: Nov 19, 2026, 6:41 PM EST
Neumora Therapeutics Employees
Neumora Therapeutics had 60 employees as of September 30, 2026. The number of employees decreased by 35 or 36.84% compared to the same quarter last year. That makes Neumora Therapeutics the 34,239th largest employer in the world and 4,514th in the United States.
Employees
60
Change (1Y)
-35
Growth (1Y)
-36.84%
Revenue / Employee
n/a
Profits / Employee
-$3,173,833
Market Cap
65.48M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Sep 30, 2026 | 60 | -35 | -36.84% |
| Jun 30, 2026 | 63 | -33 | -34.38% |
| Mar 31, 2026 | 92 | -11 | -10.68% |
| Dec 31, 2025 | 96 | -14 | -12.73% |
| Sep 30, 2025 | 95 | -14 | -12.84% |
| Jun 30, 2025 | 96 | -12 | -11.11% |
| Mar 31, 2025 | 103 | -17 | -14.17% |
| Dec 31, 2024 | 110 | -14 | -11.29% |
| Sep 30, 2024 | 109 | -1 | -0.91% |
| Jun 30, 2024 | 108 | -2 | -1.82% |
| Mar 31, 2024 | 120 | 12 | 11.11% |
| Dec 31, 2023 | 124 | 30 | 31.91% |
| Jun 30, 2023 | 110 | 16 | 17.02% |
| Mar 31, 2023 | 108 | 14 | 14.89% |
| Dec 31, 2022 | 94 | 6 | 6.82% |
| Mar 31, 2022 | 94 | 41 | 77.36% |
| Dec 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Champions Oncology | 214 |
| Fortress Biotech | 78 |
| Acrivon Therapeutics | 76 |
| Corbus Pharmaceuticals Holdings | 36 |
| Cardiff Oncology | 31 |
| NeurAxis | 24 |
| PDS Biotechnology | 21 |
| Cognition Therapeutics | 14 |
NMRA News
- 2 days ago - Neumora Therapeutics price target lowered to $8 from $14 at Guggenheim - TheFly
- 3 days ago - Neumora Therapeutics reports Q3 EPS (18c), consensus (19c) - TheFly
- 3 days ago - Neumora Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update - GlobeNewsWire
- 3 days ago - Neumora Therapeutics Earnings release: Q3 2026 - Filings
- 3 days ago - Neumora Therapeutics Quarterly report: Q3 2026 - Filings
- 21 days ago - Neumora Therapeutics price target lowered to $3 from $4 at Mizuho - TheFly
- 3 months ago - Neumora CEO transition not a surprise, says H.C. Wainwright - TheFly
- 3 months ago - Neumora Therapeutics reports Q2 EPS (23c), consensus (24c) - TheFly